An HSJ roundtable, fully funded and initiated by AbbVie, considered which pathway changes might support best use of capacity
This HSJ roundtable was fully funded and initiated by AbbVie, who worked with HSJ to decide on the topic it covers. HSJ entirely organised the event and retained editorial control over it, and this associated report. AbbVie has reviewed this report in advance of publication for factual accuracy and compliance checks.
Job Number: UK-ONC-230022
Date of Preparation: April 2024
Meeting Reference: 2023-GB-MNP-00072
Waiting times for cancer treatment have been growing for many years, but the additional pressures wrought by the early waves of the pandemic have made the situation more pressurised still. Pre-existing service and workforce challenges have been compounded, leading to pressing questions about how to best use capacity while also delivering a good patient experience.
In association with
These are complicated issues without single or simple solutions, but it may be that some of the answers lie within evolutions to pathways. A recent HSJ roundtable, initiated and fully funded by AbbVie, explored this important area through the specific prism of blood cancers.
Read the detailed report here.
Panellists
- Robert Ayto, consultant haematologist, Portsmouth Hospitals University Trust
- Linda Barton, consultant haematologist, University Hospitals of Leicester Trust and chair of haematology expert clinical advisory group, East Midlands Cancer Alliance
- Anthony Cunliffe, national lead medical adviser, Macmillan Cancer Support and joint clinical director, South East London Cancer Alliance
- Derralynn Hughes, clinical co-director, North Central London Cancer Alliance and professor of experimental haematology, University College London
- Kate Jackman, improvement delivery lead, East of England Cancer Alliance
- Anita Parmar, Macmillan cancer programme lead, University Hospitals of Leicester Trust
- Louise Powell, medical lead for haematology, AbbVie UK
- Helen Rowntree, chief executive, Blood Cancer UK
- Helen Winter, consultant medical oncologist, University Hospitals Bristol and Weston Foundation Trust and clinical director, SWAG Cancer Alliance
Job Number: UK-ONC-230022
Date of Preparation: April 2024
Meeting Reference: 2023-GB-MNP-00072
